Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs TGR 1202 (Primary) ; Ublituximab (Primary) ; Pembrolizumab
- Indications B cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 13 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 13 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
- 09 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by TG Therapeutics media release.